By Michele Maatouk
Date: Wednesday 05 Aug 2026
(Sharecast News) - Eli Lilly lifted its full-year guidance on Wednesday as weight-loss jabs Mounjaro and Zepbound drove an increase in second-quarter sales.
| Currency | US Dollars |
| Share Price | $ 1,157.08 |
| Change Today | $ -27.55 |
| % Change | -2.33 % |
| 52 Week High | $1,281.49 |
| 52 Week Low | $763.00 |
| Volume | 7,268 |
| Shares Issued | 944.80m |
| Market Cap | $1,093,209m |
| RiskGrade | 179 |
| Time | Volume / Share Price |
| 16:00 | 680,186 @ $1,157.08 |
| 15:59 | 62 @ $1,160.05 |
| 15:59 | 49 @ $1,160.01 |
| 15:59 | 100 @ $1,160.00 |
| 15:59 | 100 @ $1,160.00 |
You are here: research